Navigation Links
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
Date:6/1/2009

yeloma" (Abstract #8504).

"We are excited by the positive demonstration of patient benefit achieved in our trials of carfilzomib. In particular, the response rates and duration of response among heavily pre-treated patients who lack treatment alternatives are highly encouraging," said Michael Kauffman, M.D., Ph.D., Chief Medical Officer of Proteolix. "Based on the consistent efficacy and safety profile achieved from our preclinical and clinical studies of carfilzomib, we are focused on advancing this promising novel agent through late-stage evaluation, with an eye toward an accelerated approval."

Trial Expanded for Accelerated Approval Strategy

Based on the positive data achieved in this Phase 2 trial, Proteolix has expanded the Phase 2 study to enroll an additional 250 relapsed and refractory multiple myeloma patients. If positive, results from this study could form the basis for a New Drug Application (NDA) filing for accelerated approval with the U.S. Food and Drug Administration in 2010.

Patients initially receive 20mg/m(2) carfilzomib twice a week over a 28-day cycle, followed by doses of 27mg/m(2) for every cycle thereafter for up to twelve cycles. The primary endpoint for the Phase 2 study is overall response rate, defined as a complete response (CR) or partial response (PR). Secondary endpoints include clinical benefit response (CR, PR or minor response (MR)), duration of response, progression-free survival, time to progression, overall survival and safety. To date, more than 140 patients have been enrolled in the study. Proteolix anticipates reporting results from this accelerated approval trial in the first half of 2010.

Carfilzomib Active in Single-Agent and Combination Regimens

Proteolix also presented data from two ongoing studies of carfilzomib in multiple myeloma patients during the Lymphoma and Plasma Cell Disorders poster session.


'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
2. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
4. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
5. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
9. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
11. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 McGraw-Hill Education Professional, a leading ... technical, and medical communities, has announced the launch of ... application of the world-renowned medical education platform. ... App , available for download onto all iOS and ... to gain access to valuable AccessMedicine diagnostic ...
(Date:7/29/2014)... 2014 According to a new ... Fixation Devices Market - Global Forecast, Market Share, Size, ... orthopedic trauma fixation devices market is estimated at USD ... at a CAGR of 7.2% from 2014 to 2019, ... in 2020. Browse the Orthopedic Trauma Fixation ...
(Date:7/29/2014)... , July 29, 2014  Instrumentation Laboratory (IL) today announced ... new corporate logo. This is part of a comprehensive rebranding ... Founded in Boston, MA , in 1959, ... companies since 1992.  Other companies in the group include Inova ... Systelab ( Barcelona, Spain ).  Like IL, these ...
Breaking Medicine Technology:McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3
... SAN DIEGO, April 29, 2011 Halozyme Therapeutics, Inc. ... and commercializing products targeting the extracellular matrix , ... financial results on Friday, May 6, 2011 before the ... followed by a conference call with the investment community ...
... Pa., April 29, 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... therapeutic and preventive vaccines against cancers and infectious diseases, announced ... conferences: JMP Securities Research Conference San ... Inovio Presentation Dr. J. Joseph Kim, ...
Cached Medicine Technology:Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6 2Inovio Pharmaceuticals to Present at Investor Conferences 2Inovio Pharmaceuticals to Present at Investor Conferences 3Inovio Pharmaceuticals to Present at Investor Conferences 4
(Date:7/29/2014)... 2014 Many people complain about their dependence ... each morning is put on glasses to see their clock ... individuals also may be dissatisfied with their vision even when ... may cause difficulty driving, especially at night due to glare. ... one’s golf ball, see the TV, sew or cross stitch, ...
(Date:7/29/2014)... Alan Mozes HealthDay Reporter ... autism patients with just a single dose of the hormone ... emotions, Japanese researchers report. Known as the "love hormone," ... bonding between lovers, and between mothers and their children. ... key area of the brain that has long been associated ...
(Date:7/29/2014)... During his 37 years in dental practice, Dr. Arthur ... a steady stream of college students shadow him in order ... on to dental school and some are now practicing dentistry ... college students find success. , For students interested in applying ... to see a realistic view of what goes on in ...
(Date:7/29/2014)... headache sufferers to record the severity and regularity of ... Griffith research study. , A new approach to the ... with their triggers and is being led by Professor ... Health program. , He has developed an approach designed ... their headaches called Learning to Cope with Triggers (LCT). ...
(Date:7/29/2014)... Palm Beach, Florida (PRWEB) July 29, 2014 ... new scholarship for law students this week. The scholarship will ... of abused children and their families. , Steinger, Iscoe and ... past abuse, and want tomorrow’s attorneys to do the same. ... States each year according to the nonprofit Childhelp ...
Breaking Medicine News(10 mins):Health News:Cataract Surgery: New Technology for Reduced Dependence on Glasses 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3Health News:Arthur Bruce Dental Helps College Students 2Health News:Steinger, Iscoe & Greene Offers Child Advocate Scholarship 2
... early studies into a new treatment for patients with ... an anti-depression 'pacemaker' found the electrical device can significantly ... pacemaker, which is implanted in a person's chest, sends ... brain. The device was originally used to treat patients ...
... Hyderabad, Andhra Pradesh chief minister Chandrababu Naidu has set ... City’ in the port town of Vishakhapatnam. By providing ... hopes to attract global pharmaceutical companies to the city ... by 2005. The ‘Pharma City’ will be developed by ...
... reduces the number of seizures suffered by severe epileptics, a ... coil which was placed on the side of the head ... ,The use of high-frequency pulses has been blamed for triggering ... using low-frequency magnetism.The ten patients in the Gottingen study suffered ...
... found six genes which may play a role in breast ... to gauge an individual woman's risk of developing cancer by ... breast cancer cases are currently thought to be caused by ... firmly linked with some cases of inherited breast cancer, but ...
... to a new study combining a diet rich in ... blood pressure, even in those not suffering from hypertension. ... lead to significant health benefits.// Previous research has shown ... levels of homocysteine, an amino acid linked to heart ...
... disorder which they say is responsible for people who find ... findings could lead to new treatments for jet lag//, insomnia ... Utah say people who cannot stay awake much after 8.30pm ... a disorder called "familial advanced sleep-phase syndrome". This means the ...
Cached Medicine News:
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EGG or EMG recordings. Surface Electrodes, Skin Preparation and Conductive Cream complete the setup for a EGG study and are essenti...
Medicine Products: